Document Detail

Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding).
MedLine Citation:
PMID:  19772806     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To analyze the safety of methotrexate (MTX) in rheumatoid arthritis (RA) regarding the reproductive system (fertility, pregnancy, and breastfeeding).
METHODS: Systematic review of studies retrieved by a sensitive search strategy in Medline (1961 - October 2007), Embase (1961 - October 2007), Cochrane Library (up to October 2007), and from the abstracts of the ACR (2005, 2006) and EULAR (2005 - 2007) annual scientific meetings.
SELECTION CRITERIA: a) population: studies had to include patients with RA; b) intervention and control: discontinuation of MTX or elective abortion versus continuation of MTX or continuing pregnancy; and c) outcomes: infertility, oligospermia, reversibility, miscarriages, malformations, premature babies, healthy newborn, percent of the dose of MTX that passes to human milk, adverse effects in the lactating child. There was no limitation regarding study design, except for case reports, or language.
RESULTS: MTX and pregnancy: we selected 6 articles for detailed evaluation from 847 initial ones from the literature search. They were descriptions of cases obtained from searching retrospectively clinical databases of individual centers or from surveys. Patients had been exposed to MTX at doses used in rheumatology (5-25 mg/w), from conception to first trimester of pregnancy. Total number of MTX exposed pregnancies is 101, and the pooled outcomes (elective abortion not included): 19 miscarriages (23% of pregnancies); 55 live births (66% of pregnancies); and 5 of them had minor neonatal malformations (5% of pregnancies). The rate of induced abortions is 18%. MTX and lactation and fertility: no articles fulfilled the selection criteria. There is indirect evidence on the excretion of MTX in human milk and probably of reversible infertility from case reports.
CONCLUSIONS: This review exposes the shortage of data on the safety and risks of MTX during conception, pregnancy and lactation at the doses commonly used in rheumatology. MTX and pregnancy: there is not sufficient evidence to support whether it is MTX or the disease what underlies miscarriage in these patients. Pooling the data from the studies included, the rates of miscarriages and of birth defects are similar to the rates observed in healthy population. MTX and lactation and fertility: there is absence of confirming evidence.
J A Martínez Lopez; E Loza; L Carmona
Related Documents :
8592316 - Laparoscopic removal of a dermoid cyst in pregnancy. a case report.
20226416 - Molar ectopic pregnancy in the uterine cornus.
15971246 - Results of nonablative wrinkle reduction with a 1,450-nm diode laser: difficulties in t...
18058356 - Orthoptists' management of amblyopia - a case-based survey.
15203816 - The epidemiology of smoking during pregnancy: smoking prevalence, maternal characterist...
264166 - Transfer and dynamics of uric acid in the pregnant rhesus monkey. ii. a mathematical mo...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  27     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2009 Jul-Aug
Date Detail:
Created Date:  2009-09-23     Completed Date:  2009-11-12     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  678-84     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy*
Databases, Bibliographic
Embryonic Development / drug effects
Fertility / drug effects
Fetal Development / drug effects
Lactation / drug effects
Maternal Exposure / adverse effects*
Methotrexate / adverse effects*
Pregnancy Outcome*
Reproduction / drug effects*
Reg. No./Substance:
0/Antirheumatic Agents; YL5FZ2Y5U1/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease.
Next Document:  Current educational status of paediatric rheumatology in Europe: the results of PReS survey.